Annual Shareholders Equity
-$60.24 M
-$28.05 M-87.12%
31 December 2023
Summary:
Galectin Therapeutics annual stockholders equity is currently -$60.24 million, with the most recent change of -$28.05 million (-87.12%) on 31 December 2023. During the last 3 years, it has fallen by -$84.43 million (-349.00%). GALT annual shareholders equity is now -232.12% below its all-time high of $45.59 million, reached on 31 December 2019.GALT Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Shareholders Equity
-$92.48 M
-$10.33 M-12.58%
30 September 2024
Summary:
Galectin Therapeutics quarterly stockholders equity is currently -$92.48 million, with the most recent change of -$10.33 million (-12.58%) on 30 September 2024. Over the past year, it has dropped by -$41.61 million (-81.79%). GALT quarterly shareholders equity is now -279.15% below its all-time high of $51.62 million, reached on 30 June 2019.GALT Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Shareholders Equity Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -87.1% | -81.8% |
| 3 y3 years | -349.0% | -1099.9% |
| 5 y5 years | -973.3% | -286.9% |
GALT Shareholders Equity High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -349.0% | at low | -1099.9% | at low |
| 5 y | 5 years | -232.1% | at low | -286.9% | at low |
| alltime | all time | -232.1% | at low | -279.1% | at low |
Galectin Therapeutics Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | -$92.48 M(+12.6%) |
| June 2024 | - | -$82.15 M(+15.6%) |
| Mar 2024 | - | -$71.09 M(+18.0%) |
| Dec 2023 | -$60.24 M(+87.1%) | -$60.24 M(+18.4%) |
| Sept 2023 | - | -$50.87 M(-0.5%) |
| June 2023 | - | -$51.13 M(+19.9%) |
| Mar 2023 | - | -$42.65 M(+32.5%) |
| Dec 2022 | -$32.19 M(-1330.7%) | -$32.19 M(+44.1%) |
| Sept 2022 | - | -$22.34 M(+46.7%) |
| June 2022 | - | -$15.22 M(+145.8%) |
| Mar 2022 | - | -$6.19 M(-336.7%) |
| Dec 2021 | $2.62 M(-89.2%) | $2.62 M(-71.7%) |
| Sept 2021 | - | $9.25 M(-46.0%) |
| June 2021 | - | $17.12 M(-6.1%) |
| Mar 2021 | - | $18.23 M(-24.6%) |
| Dec 2020 | $24.19 M(-46.9%) | $24.19 M(-23.3%) |
| Sept 2020 | - | $31.54 M(-14.8%) |
| June 2020 | - | $37.01 M(-13.4%) |
| Mar 2020 | - | $42.75 M(-6.2%) |
| Dec 2019 | $45.59 M(+561.0%) | $45.59 M(-7.9%) |
| Sept 2019 | - | $49.48 M(-4.1%) |
| June 2019 | - | $51.62 M(+654.5%) |
| Mar 2019 | - | $6.84 M(-0.8%) |
| Dec 2018 | $6.90 M(+478.2%) | $6.90 M(-23.1%) |
| Sept 2018 | - | $8.97 M(-8.2%) |
| June 2018 | - | $9.78 M(+269.1%) |
| Mar 2018 | - | $2.65 M(+122.0%) |
| Dec 2017 | $1.19 M(-90.1%) | $1.19 M(-55.3%) |
| Sept 2017 | - | $2.67 M(-54.1%) |
| June 2017 | - | $5.82 M(-39.6%) |
| Mar 2017 | - | $9.63 M(-19.8%) |
| Dec 2016 | $12.02 M(-52.0%) | $12.02 M(-0.1%) |
| Sept 2016 | - | $12.03 M(-17.7%) |
| June 2016 | - | $14.61 M(-25.2%) |
| Mar 2016 | - | $19.54 M(-22.0%) |
| Dec 2015 | $25.05 M(-10.5%) | $25.05 M(+26.6%) |
| Sept 2015 | - | $19.79 M(-20.1%) |
| June 2015 | - | $24.77 M(-13.6%) |
| Mar 2015 | - | $28.68 M(+2.5%) |
| Dec 2014 | $27.97 M(+240.0%) | $27.97 M(-6.6%) |
| Sept 2014 | - | $29.94 M(-7.7%) |
| June 2014 | - | $32.45 M(-7.2%) |
| Mar 2014 | - | $34.96 M(+325.0%) |
| Dec 2013 | $8.23 M(+3.9%) | $8.23 M(+0.7%) |
| Sept 2013 | - | $8.17 M(+119.3%) |
| June 2013 | - | $3.73 M(-34.9%) |
| Mar 2013 | - | $5.72 M(-27.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $7.92 M(+80.1%) | $7.92 M(+159.0%) |
| Sept 2012 | - | $3.06 M(-37.7%) |
| June 2012 | - | $4.91 M(-28.1%) |
| Mar 2012 | - | $6.82 M(+55.2%) |
| Dec 2011 | $4.40 M(-359.6%) | $4.40 M(+434.3%) |
| Sept 2011 | - | $823.00 K(-10.1%) |
| June 2011 | - | $915.00 K(-753.6%) |
| Mar 2011 | - | -$140.00 K(-91.7%) |
| Dec 2010 | -$1.69 M(-62.1%) | -$1.69 M(-40.1%) |
| Sept 2010 | - | -$2.83 M(-3.3%) |
| June 2010 | - | -$2.92 M(-49.4%) |
| Mar 2010 | - | -$5.78 M(+29.4%) |
| Dec 2009 | -$4.47 M(+852.5%) | -$4.47 M(+10.0%) |
| Sept 2009 | - | -$4.06 M(+21.7%) |
| June 2009 | - | -$3.34 M(+58.6%) |
| Mar 2009 | - | -$2.10 M(+348.4%) |
| Dec 2008 | -$469.00 K(-84.0%) | -$469.00 K(+22.5%) |
| Sept 2008 | - | -$383.00 K(-46.3%) |
| June 2008 | - | -$713.00 K(-77.5%) |
| Mar 2008 | - | -$3.16 M(+8.2%) |
| Dec 2007 | -$2.92 M(>+9900.0%) | -$2.92 M(+66.9%) |
| Sept 2007 | - | -$1.75 M(-359.6%) |
| June 2007 | - | $675.00 K(+36.6%) |
| Mar 2007 | - | $494.00 K(-2345.5%) |
| Dec 2006 | -$22.00 K(-100.6%) | -$22.00 K(-246.7%) |
| Sept 2006 | - | $15.00 K(-100.7%) |
| June 2006 | - | -$2.03 M(-43.5%) |
| Mar 2006 | - | -$3.60 M(-200.3%) |
| Dec 2005 | $3.58 M(-64.5%) | $3.58 M(-32.7%) |
| Sept 2005 | - | $5.33 M(-24.0%) |
| June 2005 | - | $7.00 M(-19.5%) |
| Mar 2005 | - | $8.70 M(-13.9%) |
| Dec 2004 | $10.11 M(+32.5%) | $10.11 M(-17.3%) |
| Sept 2004 | - | $12.22 M(+44.3%) |
| June 2004 | - | $8.47 M(+44.7%) |
| Mar 2004 | - | $5.85 M(-23.2%) |
| Dec 2003 | $7.62 M(+371.7%) | $7.62 M(+60.5%) |
| Sept 2003 | - | $4.75 M(+165.4%) |
| June 2003 | - | $1.79 M(-20.6%) |
| Mar 2003 | - | $2.25 M(+39.4%) |
| Dec 2002 | $1.62 M(+32.9%) | $1.62 M(+38.7%) |
| Sept 2002 | - | $1.17 M(+242.8%) |
| June 2002 | - | $339.90 K(-34.1%) |
| Mar 2002 | - | $515.60 K(-57.6%) |
| Dec 2001 | $1.22 M | $1.22 M(+150.4%) |
| Sept 2001 | - | $485.60 K(-170.3%) |
| June 2001 | - | -$690.60 K |
FAQ
- What is Galectin Therapeutics annual stockholders equity?
- What is the all time high annual shareholders equity for Galectin Therapeutics?
- What is Galectin Therapeutics annual shareholders equity year-on-year change?
- What is Galectin Therapeutics quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly shareholders equity year-on-year change?
What is Galectin Therapeutics annual stockholders equity?
The current annual shareholders equity of GALT is -$60.24 M
What is the all time high annual shareholders equity for Galectin Therapeutics?
Galectin Therapeutics all-time high annual stockholders equity is $45.59 M
What is Galectin Therapeutics annual shareholders equity year-on-year change?
Over the past year, GALT annual stockholders equity has changed by -$28.05 M (-87.12%)
What is Galectin Therapeutics quarterly stockholders equity?
The current quarterly shareholders equity of GALT is -$92.48 M
What is the all time high quarterly shareholders equity for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly stockholders equity is $51.62 M
What is Galectin Therapeutics quarterly shareholders equity year-on-year change?
Over the past year, GALT quarterly stockholders equity has changed by -$41.61 M (-81.79%)